



Muscle Sympathetic Reactivity to Apneic and Exercise Stress in High-Altitude Sherpa

Busch, Steven; Simpson, Lydia; Sobierajski, Frances; Riske, Laurel ; Ainslie, Philip ; Willie, Christopher ; Stembridge, Mike; Moore, Jonathan; Steinback, Craig

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

DOI:
[10.1152/ajpregu.00119.2019](https://doi.org/10.1152/ajpregu.00119.2019)

Published: 01/03/2020

Peer reviewed version

[Cyswllt i'r cyhoeddiad / Link to publication](#)

Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):

Busch, S., Simpson, L., Sobierajski, F., Riske, L., Ainslie, P., Willie, C., Stembridge, M., Moore, J., & Steinback, C. (2020). Muscle Sympathetic Reactivity to Apneic and Exercise Stress in High-Altitude Sherpa. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, 318(3), R493-R502. <https://doi.org/10.1152/ajpregu.00119.2019>

Hawliau Cyffredinol / General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Muscle Sympathetic Reactivity to Apneic and Exercise Stress in High-Altitude Sherpa

First Author (Short Title): Busch (Sympathetic Reactivity in Sherpa)

¹Stephen A Busch(MSc), ²Lydia L Simpson(MSc), ¹Frances Sobierajski(BSc), ¹Laurel Riske(Bkin), ³Philip N Ainslie(PhD), ³Chris K Willie (PhD), ⁴Mike Stembridge(PhD), ²Jonathan P Moore(PhD) , ¹Craig D Steinback(PhD)

¹Neurovascular Health Lab, Faculty of Kinesiology, Sport, & Recreation; ²School of Sport, Health & Exercise Sciences, Bangor University, Bangor, United Kingdom; ³Centre for Heart, Lung, and Vascular Health, University of British Columbia Okanagan, Kelowna, Canada; ⁴Cardiff Centre for Exercise and Health, Cardiff School of Sport and Health, Cardiff Metropolitan University, Cardiff, United Kingdom.

****Drs M Stembridge, JP Moore and CD Steinback share senior co-authorship**

Corresponding Author:

Craig Steinback, PhD
Assistant Professor
Faculty of Kinesiology, Sport, & Recreation, University of Alberta
1-059A Li Ka Shing Centre for Health Research Innovation
8602 - 112 St, Edmonton, Alberta, Canada, T6G 2E1
Tel:(780)492-5553
Fax:(780)492-4249
craig.steinback@ualberta.ca

Total Word Count: 7973

1 ABSTRACT

2 Lowland-dwelling populations exhibit persistent sympathetic hyperactivity at altitude that alter
3 vascular function. High altitude populations, such as Sherpa, have previously exhibited greater
4 peripheral blood flow in response to acute stress than Lowlanders which may be explained
5 through lower sympathetic activity. Our purpose was to determine if Sherpa exhibit lower
6 sympathetic reactivity to stress than Lowlanders. Muscle sympathetic activity (MSNA;
7 microneurography) was measured at rest in Lowlanders (n=14; age=27±6yrs) at 344m and
8 following a 8-9 days at 5050m. Sherpa (age=32±11yrs) were tested at 5050m (n=8).
9 Neurovascular reactivity (ie. change in MSNA patterns) was measured during maximal end-
10 expiratory apnea, isometric hand-grip (IHG; 30% maximal voluntary contraction for 2-minutes)
11 and post-exercise circulatory occlusion (PECO; 3-minutes). Burst frequency (bursts/min),
12 incidence (bursts/100HB), and total normalized SNA (au/min) was analyzed at rest, immediately
13 prior to apnea breakpoint, and during the last minute of IHG and PECO. Vascular responses to
14 apnea, IHG, and PECO were also measured. MSNA reactivity to apnea was smaller in Sherpa
15 than Lowlanders at 5050m, though blood pressure responses were similar between groups.
16 MSNA increases in Lowlanders during apnea at 5050m were significantly lower than at 344m
17 ($P<0.05$), indicating possible sympathetic ceiling was reached in Lowlanders at 5050m. MSNA
18 increased similarly during IHG/PECO in Lowlanders at both 334m and 5050m, and Sherpa at
19 5050m, while vascular changes (mean brachial arterial pressure, contralateral brachial
20 flow/resistance) were similar between groups. Sherpa demonstrate overall lower sympathetic
21 reactivity which may be a result of heightened vascular responsiveness to potential apneic stress
22 at altitude.

23 INTRODUCTION

24

25 The response to both acute (18, 21, 30, 31, 36) and chronic (e.g. altitude) (6, 13, 22, 25)
26 reductions of oxygen availability in lowland dwelling populations is an increase in basal efferent
27 sympathetic activity (SNA). This sympathoexcitation occurs in conjunction with local dilation to
28 facilitate blood flow redistribution and oxygen delivery to critical tissues. Previous findings also
29 show an augmented SNA response to exercise (i.e. increased sympathetic reactivity) under acute
30 hypoxic conditions (18, 33) . Whether a similar potentiation occurs during chronic hypoxia is
31 unknown. As Lowlanders exhibit heightened SNA at altitude, we propose a similar potentiation
32 of sympathetic reactivity to additional stress. Furthermore, whether similar responses are evident
33 in those exposed to long duration hypoxia, such as high altitude natives has not been studied.
34 Nepalese/Tibetan Sherpa have resided at high altitude (>2500m) for thousands of years, allowing
35 for unique evolutionary phenotypic adaptations under chronic hypoxia exposure. This includes
36 not only cardiovascular adaptations that allow for increased oxygen delivery and metabolism at
37 the local tissue (7, 9, 41) , but also overall lower SNA at rest compared to Lowlanders at altitude
38 (35) . Limited data suggest that Sherpa exhibit an improved ability to increase systemic blood
39 flow at altitude (9, 32) , while also showing greater capillary density within skeletal muscle (19)
40 and improved ability to increase leg blood flow (32) . Given our previous findings have shown
41 that Sherpa exhibit lower basal MSNA compared to Lowlanders (35) ; we hypothesize that these
42 differences in vascular function between Lowlanders and Sherpa may also translate to lower
43 sympathetic reactivity to acute apneic/exercise stress.

44

45 To address the hypothesis, we performed microneurographic recordings of efferent post-
46 ganglionic nerve activity in Lowland dwellers at low (344m) and high (5050m) altitudes and in a
47 group of native Sherpa at altitude (5050m). This was complemented with brachial
48 ultrasonography to determine the effect of heightened sympathetic stress on vascular function
49 during stress in Sherpa and acclimatized Lowlanders.

50

51 **METHODS**

52 This study was carried out within the framework of the 2016 UBC Nepal Expedition to the
53 Ev-K2-CNR Research Facility (5050m) (40) . Though participants took part in a number of
54 independent investigations, experiments were organized to ensure no contamination between
55 studies, and each study addressed distinct *a priori* research questions. Baseline demographics,
56 cardiovascular characteristics and heart rate responses to apnea have been previously reported
57 from Lowlanders and Sherpa at altitude (3, 38) , while metrics of basal SNA have also been
58 previously reported by our group (35) . Therefore, basal SNA data is included as a complement
59 for the novel independent analyses related to sympathetic reactivity.

60

61 **Study Participants**

62 Fourteen Lowlanders (27±6yrs; 2 female) and ten Sherpa (32±11yrs; 0 female) from the
63 Khumbu region of Nepal participated after providing informed written consent in their native
64 language. Procedures were explained in Nepalese and English as needed, and were approved by
65 the University of Alberta Biomedical Research Ethics Board, University of British Columbia
66 Clinical Research Ethics Board, and Nepal Health Research Council. Participants were free of
67 ventilatory, cardiovascular, metabolic, and neurological disorders as determined by a self-

68 reported health history questionnaire. Four Sherpa were self-reported smokers (0.4 ± 0.7 pack
69 years).

70

71 **Testing Location(s)**

72 The ascent profile and testing schedules are outlined in Supplemental Figures 1
73 (<https://doi.org/10.6084/m9.figshare.8066717>), 2 (<https://doi.org/10.6084/m9.figshare.8066711>),
74 and 3 (<https://doi.org/10.6084/m9.figshare.8066714.v1>). Pre-expedition testing of Lowlanders
75 ($n=14$) was performed at 344m (Kelowna, Canada). To match the ascent profile and
76 acclimatization process between groups, Sherpa were flown to Kathmandu, Nepal (1400 m),
77 where they resided between 5-15 days. Both Lowlanders and Sherpa flew to Lukla, Nepal
78 (2840m) and followed a 9-10 day ascent. One lowlander was administered oral acetazolamide
79 (half life - 4 hrs) and another was administered an intramuscular injection of dexamethasone
80 (half life – 3 hours) following 4 days arrival at 5050m for the treatment of acute mountain
81 sickness; however, both were tested after a 48-hour washout. Sherpa were not on any medication
82 and were tested on days 1-3 following arrival at 5050m, while Lowlanders were tested between
83 days 1-10 (Supplemental figure 2).

84

85 ***Study Protocol***

86 Following instrumentation, basal SNA and cardiovascular function were measured during 10
87 minutes of quiet rest. Sympathetic reactivity was subsequently assessed using two protocols: 1) a
88 volitional end-expiratory apnea at functional residual capacity (23) and 2) isometric hand-grip
89 (IHG) performed for 2 min followed by 3 min of post-exercise circulatory occlusion (PECO).
90 Prior to apnea, an investigator paced the participants' breathing (2-3 breaths) to maintain rate and

91 depth, while preventing hyperventilation. Participants were then instructed to “hold their breath
92 for as long as possible. Participants performed IHG at 30% of their previously determined
93 maximal voluntary contraction using handgrip dynamometer (Grip Force Transducer;
94 ADInstruments, Australia). Immediately following 2 minutes of IHG, a manual blood pressure
95 cuff was inflated (>200mmHg) for 3 minutes to stimulate post-exercise ischemia while the limb
96 was relaxed. The apnea protocol always preceded IHG/PECO protocol.

97

98 **Experimental Measures**

99 All participants were tested in the supine position. ECG (Lead II) and the arterial blood
100 pressure waveforms (finger photoplethysmography; Finometer Pro, Finapres Medical Systems,
101 Netherlands) were collected continuously at 1 KHz (ADInstruments, Chart Pro v8.3.1,
102 Australia). Heart rate (HR) was calculated from the ECG R-R interval. Beat-by-beat cardiac
103 output (CO) was calculated using the Model Flow algorithm and used to calculate total
104 peripheral resistance ($TPR = MAP/CO$). Beat-by-beat mean (MAP), systolic (SBP) and diastolic
105 (DBP) pressures were calculated from the arterial pressure waveform that was calibrated against
106 manual sphygmometry.

107

108 ***Muscle Sympathetic Nerve Activity***

109 Microneurography was used to directly measure efferent muscle sympathetic vasomotor nerve
110 activity (MSNA) (11, 35, 37) . A tungsten microelectrode (200 μ m diameter, 35 mm long, tapered
111 to a 1-5 μ m uninsulated tip) was inserted percutaneous into the peroneal (common fibular) nerve,
112 with an uncoated tungsten reference electrode inserted subcutaneously 1-3 cm from the recording
113 site. The recording electrode was manipulated until a pulse-synchronous bursting pattern was

114 identifiable in response to apnea but not a loud noise (4) . The raw MSNA signal was amplified
115 (1000x pre-amplifier and 100x variable gain isolated amplifier), band pass filtered (700-
116 2,000Hz), rectified, and integrated (decay constant 0.1s) to obtain a mean voltage neurogram
117 (model 662C-3; Iowa University Bioengineering; USA). Both raw and integrated signals were
118 sampled at 10 KHz (ADInstruments, Chart Pro v8.3.1; Australia).

119

120 ***Vascular Ultrasonography***

121 Of the 22 participants tested, ultrasonography was successfully obtained a subset of
122 Lowlanders (n= 8) and Sherpa (n = 4). Ultrasonography was used to measure brachial artery
123 (BA) diameter, Doppler velocity (BA_v), and flow (BA_F) in the non-exercising arm at baseline
124 and during the IHG/PECO protocols (12 ~MHz linear array transducer; Vivid Q, GE
125 Healthcare). Probe insonation-angle was kept constant (60°) across all tests. Video capture was
126 used for recording vessel diameter (DVI2USB3.0; EpiPhan Systems, Canada) and was stored
127 off-line in audio video interleave format for future analysis with edge detection software
128 (Brachial Analyzer, Medical Imaging Applications, USA). Image analysis of data was performed
129 at 30Hz following visual confirmation (SAB) of the region of interest to ensure clearly
130 distinguishable lumen walls. BA flow velocity waveforms were converted from Doppler audio
131 signals (qDAT; Penn State, USA) (14) and stored offline at 1 KHz (ADInstruments, Chart Pro
132 v8.3.1).

133

134 **Data and Statistical Analysis**

135 Resting MSNA and cardiovascular data was averaged over ~10 minutes. MSNA bursts were
136 identified using a semi-automated detection algorithm (Chart Pro 8.3.1) and confirmed by a

137 trained observer (SAB). Resting MSNA was quantified as burst frequency (bursts/min),
138 incidence (bursts/100 HB), and normalized burst amplitude (% of maximal burst size at baseline)
139 and area (area under the curve, [au]). For the apnea protocol, MSNA and cardiovascular data
140 were analyzed from the final 10 cardiac cycles prior to volitional breakpoint. Cardiovascular
141 post-apnea nadir (S_pO_2 , HR) and peak (SBP, DBP, MAP) responses were obtained in 10-15
142 seconds post breakpoint. MSNA bursts during the apnea were calculated as the burst area (area
143 under the curve, [au]) during the last 10 cardiac cycles prior to volitional breakpoint. Burst area
144 was normalized SNA (au/min) during baseline and apnea to account for variations in cardiac
145 cycle length and burst width (3) . In addition, the average likelihood (%) of a burst occurring
146 during a given cardiac cycle for apneas was calculated across participants. Sympathetic reactivity
147 to apnea was assessed as the increase in normalized burst area was compared between baseline
148 and end-apnea. MSNA (frequency, incidence and normalized amplitude) and cardiovascular data
149 (HR, blood pressure, TPR, and BA_F) were averaged during the last minute of both IHG and
150 PECO. Sympathetic reactivity was assessed as the increase in MSNA from baseline to IHG and
151 PECO. Finally, an indirect measure of neurovascular transduction was performed to determine
152 the translation of sympathetic outflow on vascular outcomes (delta change in TPR over the delta
153 change in delta burst frequency [au]) across groups during the IHG/PECO protocols.

154

155 Results are reported as mean \pm standard deviation (SD) with the exception of baseline burst
156 amplitude, which is reported as median \pm interquartile range (IQR) to account for differences in
157 amplitude distribution between conditions. Multiple comparisons were assessed for all
158 measurements using pre-planned contrasts of Lowlanders from low to high altitude (paired t-
159 tests), and Lowlanders to Sherpa at high altitude (unpaired t-tests) with an adjusted alpha (α')

160 value corrected for multiple comparisons (c). This was performed by adjusting the *a priori* alpha
161 (α , 0.05) using the experiment-wise error rate (α_e) (3, 15) :

$$a' = \frac{\alpha_e}{c}$$

$$163 \quad \alpha_e = 1 - (1 - \alpha)^c$$

164
165 For normalized bursts amplitude, and vascular responses during baseline, IHG, and PECO
166 protocols, a two-way repeated measures ANOVA compared the main and interaction effects in
167 the distributions between conditions. Statistical analysis for normalized total peak SNA and change in
168 mean arterial pressure was performed via one-way ANOVA between Lowlanders at low altitude,
169 Lowlanders at High Altitude. To address the potential effect of duration at altitude on resting
170 MSNA; a secondary analysis via Pearson's moment correlation analysis of dependent variables
171 was performed in this study. Finally, ANCOVA analysis was used to control for duration at
172 altitude. All statistical analyses were performed using SigmaPlot 13 (Systat Software, Chicago,
173 IL).

174 175 **RESULTS**

176 Fourteen lowlanders were successfully tested at 344m and again at 5050m. Two
177 Lowlanders reported having mild acute mountain sickness (AMS) on the day of testing (Lake
178 Louise scores of 3). However, the data from these two subjects were comparable to the averaged
179 responses and therefore included in the main analyses. Eight of the ten Sherpa who descended to
180 Kathmandu were successfully tested at 5050m. No relationship was shown in this study between
181 duration after arriving at 5050m and resting MSNA in either Lowlanders (Burst Frequency $r^2 =$
182 0.160, $p = 0.065$) or Sherpa (Burst Frequency $r^2 = 0.001$, $p = 0.937$). Baseline cardiovascular and

183 autonomic characteristics for both Sherpa and Lowlanders are listed in Table 1. SBP, DBP,
184 MAP, CO, TPR, and SpO₂ were not different between lowlanders and Sherpa at 5050m

185

186 **Baseline Neurovascular Characteristics in Sherpa and Lowlanders**

187 Resting MSNA values for Sherpa and Lowlanders have been reported previously
188 reported (35), but are displayed in Tables 1 for completeness. Briefly, Lowlanders burst
189 frequency tripled (11 ± 5 bursts/min to 30 ± 7 bursts/min; $p < 0.001$) while burst incidence
190 doubled (25 ± 13 bursts/100 HB to 50 ± 15 bursts/100 HB; $p < 0.001$) following several days at
191 high altitude. At 5050m, Sherpa had a lower burst frequency (23 ± 11 bursts/min; $p < 0.05$) and
192 incidence (30 ± 13 bursts/100 HB; $p < 0.05$) compared to Lowlanders at 5050m. At altitude the
193 distribution of normalized burst area was also shifted towards larger sized bursts in Lowlanders,
194 with the burst amplitude distributions in the Sherpa being similar to that of Lowlanders at
195 5050m. After taking into account differences in both frequency and amplitude distribution, total
196 basal sympathetic activity was similar in Sherpa (1103 ± 520 au/min) and Lowlanders at 5050m
197 (1320 ± 520 au/min; $P = 0.385$) with both being higher than observed in lowlanders at low altitude
198 (451 ± 206 au/min; $p < 0.05$).

199 **Sympathetic Reactivity to Apnea in Lowlanders and Sherpa**

200 Sympathetic neurovascular reactivity during apnea was assessed in 14 Lowlanders at low
201 and high altitude, and 8 Sherpa assessed at 5050m. At low altitude, Lowlanders had an apnea
202 duration of 30.4 ± 11.1 s (range 15-74s) which was reduced to 15.4 ± 5.3 s (range 9-27s)
203 ($P < 0.001$) at 5050m. Lowlanders SpO₂ nadir post-apnea was $78 \pm 7\%$. Sherpa apnea duration
204 (15.8 ± 2.6 ; Range 12-19s; $P = 0.84$) and saturation ($75 \pm 5\%$; $P = 0.329$) post-apnea were not
205 different to that of Lowlanders.

206 Apnea across all groups and conditions produced a very robust increase in MSNA driven
207 by changes in both burst occurrence and burst area (Figures 1-3). Apnea at low altitude was
208 associated with a significant increase in MSNA in Lowlanders (normalized total area $+31359 \pm$
209 30383 au/min compared to baseline; $P < 0.01$). While apnea at altitude resulted in the largest burst
210 augmentation and increase in burst occurrence (Figure 2), this occurred over a longer time due to
211 a previously reported bradycardia response (3) Thus, the au/min response to apnea tended to be
212 less at high altitude ($+17711 \pm 11018$ au/min) versus low altitude ($+31359 \pm 30434$ au/min;
213 $p = 0.063$). Interestingly, 5 out of the 14 Lowlanders had “prolongation” of sympathetic bursts
214 during apnea at high altitude that did not represent normal burst firing characteristics. More
215 specifically, the cyclical modulation of efferent bursts activity was altered at 5050m such that
216 bursts became broader and less peaked, encompassing a larger portion of the cardiac cycle
217 (Figure 1). In addition, there was a brief period post-apnea where no bursts occurred (approx. 5-
218 10 seconds) immediately following volitional breakpoint, after which ‘characteristic bursts’
219 returned to those observed pre-apnea. In contrast, Sherpa sympathetic responses to apnea ($+7708$
220 ± 4312 au/min) were significantly lower than Lowlanders at low altitude ($P = 0.048$) and at
221 5050m ($P = 0.027$). Additionally, there were no observed cases of “prolonged” bursts in Sherpa
222 neurograms.

223 Apnea resulted in a significant increase in mean blood pressure in all three groups; $34 \pm$
224 13 mmHg in Lowlanders at low altitude, 35 ± 20 mmHg in Lowlanders at 5050m and 23 ± 8
225 mmHg in Sherpa at 5050m (all $P < 0.01$ with respect to baseline) (Figure 3). The increase in
226 MAP associated with apnea was smallest in Sherpa ($P = 0.028$ when compared to Lowlanders at
227 334m). When these responses were considered together Sherpa had higher vascular
228 responsiveness to sympathetic activation during apnea (3.70 ± 1.90 mmHg/au/min $\times 10^{-3}$)

229 compared to Lowlander at low (1.84 ± 1.17 mmHg/au/min $\times 10^{-3}$, $P < 0.01$) but not high ($2.62 \pm$
230 1.81 mmHg/au/min $\times 10^{-3}$, $P = 0.227$) altitude.

231

232 **Sympathetic and Vascular Reactivity to Isometric Hand Grip and Post Exercise**

233 **Circulatory Occlusion**

234 Sympathetic neurovascular reactivity during the IHG/PECO protocols was assessed in 14
235 Lowlanders at low and high altitude, and was successfully collected in 6 Sherpa 5050m. At
236 altitude, Sherpa exhibited an overall lower burst frequency, incidence and total MSNA during
237 the BL, IHG and PECO compared to acclimatized Lowlanders (Figure 4, each $P < 0.001$). During
238 IHG burst frequency ($+17 \pm 9$, $+18 \pm 13$, and $+16 \pm 12$ bursts/min; all $P < 0.001$), burst incidence
239 ($+14 \pm 15$, $+5 \pm 15$, and $+13 \pm 13$ bursts/100 HB; all $P < 0.001$) and total MSNA ($+1429 \pm 893$,
240 $+1247 \pm 1178$, and $+1827 \pm 1361$ au/min; all $P < 0.001$) were elevated significantly in Lowlanders
241 at 344m and 5050m, and Sherpa at 5050m respectively (Figure 4). No further increase in burst
242 frequency or total MSNA occurred between IHG and PECO, although burst incidence climbed
243 due to the concurrent return of heart rate to baseline during PECO (Figure 5). The increase in
244 MSNA occurring with IHG/PECO was not different between groups.

245 While Sherpa tended to have an overall lower blood pressure (Main effect of group
246 $P = 0.32$; $P = 0.27$ versus Lowlanders in Kelowna; $P = 0.93$ versus Lowlanders at 5050m), the
247 absolute change in blood pressure response to IHG and PECO were similar between Sherpa
248 ($+15 \pm 4$ and $+12 \pm 6$ mmHg) and Lowlanders ($+15 \pm 6$ and $+12 \pm 8$ mmHg) at 5050m (Figure 5;
249 $P = 0.829$ for IHG, $P = 0.778$ for PECO). The change in total peripheral resistance was also
250 similar between Sherpa ($+2.6 \pm 2.8$ and $+2.9 \pm 2.9$ mmHg/L/min) and Lowlanders (-0.7 ± 1.9 and

251 +0.6± 1.7 mmHg/L/min) at 5050m (P=0.791 for IHG, P=0.836 for PECO). Thus, unlike the
252 apnea protocol we did not detect significant differences in neurovascular reactivity during IHG /
253 PECO stress with altitude (in Lowlanders) or between groups (at 5050m). Indirect transduction
254 analysis revealed that Sherpa showed greater vascular transduction than Lowlanders at 344m
255 (+151.7± 73.1 versus -74.7 ±184.7 au; P=0.015), but not Lowlanders at 5050m (0.9± 262.0 au;
256 P=0.198), during the IHG protocol. However, the transduction response was similar across all
257 groups during the PECO protocol, respectively (+178.2 ± 142.5; +214.0± 131.0 [P=0.657 versus
258 Sherpa]; and +7.5 ± 279.6 [P =0.187 versus Sherpa] au).

259

260 **Forearm Blood Flow Reactivity in Lowlanders and Sherpa**

261 Brachial artery blood flow was successfully analyzed in a subset of 8 Lowlanders and 4
262 Sherpa during the HG/PECO protocol (Figure 6). Basal forearm blood flow was not different
263 between Lowlanders at 344m (46± 39 mL/min), 5050m (22± 42 mL/min), or Sherpa at 5050m
264 (56± 24 ml/min) (Main effect of Group, P=0.080). Both IHG and PECO saw no change in
265 contralateral brachial blood flow for Sherpa (+8± 23, P=0.836 and +11± 38 mL/min, P=0.522
266 respectively) and Lowlanders (+29± 25, P=0.624 and +22± 42 mL/min, P= 0.644 respectively)
267 at 5050m. The HG and PECO protocols did not result in a change in contralateral brachial
268 resistance for Sherpa (-0.3± 1.1, P=0.879 and 0.1± 0.8 mmHg/mL/min, P=0.987 respectively)
269 and Lowlanders (-0.6± 1.0, P=0.945 and -0.2± 0.9 mmHg/mL/min, P=0.898 respectively) at
270 5050m, similar to blood pressure results (above). However, analysis of conductance proved more
271 sensitive, indicating significant main effect for brachial artery conductance (P=0.049), with
272 Lowlanders having a higher brachial artery conductance at altitude than Sherpa (P=0.047, Figure

273 6). Nonetheless, there remained no absolute change in conductance during IHG and PECO for
274 either Sherpa (-0.1 ± 0.3 and -0.1 ± 0.5 mmHg/mL/min) or Lowlanders ($+0.2 \pm 0.3$ and $+0.1 \pm 0.5$
275 mmHg/mL/min) at 5050m.

276

277 **DISCUSSION**

278 This study demonstrates that sympathetic neural activation (i.e. increases in MSNA) in
279 response to acute apneic stress appears lower in Lowlanders following acclimatization. However,
280 this is due to the unique nature maximal volitional apneas. Nonetheless, Sherpa had a lesser
281 response compared to acclimatizing Lowlanders at 5050m and Lowlanders at low altitude
282 (334m). This lower MSNA response in Sherpa was offset by a greater vascular reactivity to
283 sympathetic activation. During isometric hand-grip and post-exercise circulatory occlusion,
284 sympathetic activation was observed to be much lower than the apneic stress, and no differences
285 were noted between groups with respect to sympathetic activation or vascular responses.

286

287 *MSNA responses to apneic and hand-grip / post-exercise circulatory occlusion stressors*

288 Apnea proved to be a significant sympathetic stressor, both at low and high altitude.
289 Although acclimatized Lowlanders demonstrated 100% burst occurrence and the greatest burst
290 augmentation (i.e. increase in burst area), normalized total activity remained lower than that
291 measured at low altitude. This was due to a previously reported bradycardia¹⁶ that limits burst
292 frequency. Thus, an apparent “sympathetic ceiling” may be reached during apnea in chronic
293 hypoxic conditions. Despite similar apnea durations and desaturation in Sherpa compared to
294 acclimatized Lowlanders, the Sherpa demonstrated a lower burst occurrence, lower burst

295 augmentation and a lower total MSNA response to apnea. Importantly, this occurred without an
296 apparent limitation on burst frequency (i.e. no bradycardia). These data indicate that Sherpa are
297 less responsive to apneic stress under the same hypoxic conditions as acclimatized lowlanders.
298 This also suggests that Sherpa have a greater functional sympathetic reserve, whereby they may
299 theoretically be able to increase MSNA more than observed in the current study. In contrast to
300 apneic stress, the MSNA response to the IHG/PECO protocol was appreciably smaller (although
301 not assessed statistically). Although a main effect of group was present, with acclimatized
302 Lowlanders having the highest activity, all three groups exhibited similar increases in MSNA
303 burst frequency, incidence, and total activity during IHG/PECO.

304

305 Previous studies in Lowlanders under acute hypoxic exposure demonstrate further MSNA
306 potentiation during dynamic exercise compared to normoxia. (18, 34) Since the ascent to
307 altitude causes further reductions in oxygen availability to the local tissue alongside concurrent
308 MSNA augmentation, we hypothesized that altitude would also be associated with an augmented
309 SNA response to IHG and PECO. However, the lack of difference in the response at low and
310 high altitudes demonstrate that chronic hypoxic stress compounded with further metabolic
311 activation (albeit in one isolated limb during an isometric exercise) does not alter the MSNA
312 response. Therefore, MSNA reactivity to metaboreflex stress appears preserved in acclimatized
313 Lowlanders. We believe that this may be explained through several myogenic adaptations during
314 acclimatization that favor anaerobic metabolism under chronic hypoxia exposure. With long-
315 term exposure to altitude there has been previously noted reductions of muscle oxidative
316 capacity (16) associated with muscle atrophy and catabolism (2) in addition to a shift away
317 from FA enzyme oxidation during rest and exercise (29) . These potential adaptations during

318 longer periods of residency at altitude would improve anaerobic metabolism, reduce metabolic
319 strain and overall sympathetic activation compared to exertion during an acute period of hypoxia
320 exposure. These adaptations may be time dependant, with shorter periods of exposure not
321 appearing to show any significant changes in skeletal muscle function or morphology (26) .
322 Therefore, any potential myogenic adaptations that may exist in the first week of acclimatization
323 for Lowlanders does not appear to directly affect efferent sympathetic outflow. Previous data
324 have indicated lower mitochondrial density (19) , improved ATP to O₂ yield and greater energy
325 production at a lower oxygen cost in Sherpa (17) . Sherpa have also previously demonstrated
326 increased ability to augment femoral blood flow velocity post-circulatory occlusion compared to
327 Lowlanders (32) . For these reasons, we hypothesized that Sherpa would have a lower MSNA
328 response to the IHG/PECO protocol. Counter to this hypothesis, we observed that Sherpa had a
329 similar increase in MSNA during IHG/PECO. It is worth noting that MSNA was lower in
330 Sherpa compared to acclimatized Lowlanders through baseline and IHG/PECO. Thus, the above
331 noted mechanisms could still be involved in shifting the MSNA relationship lower, but keep the
332 same gain of the response to metabolic stress.

333

334 **Neurovascular Reactivity between Lowlanders and Sherpa at Altitude**

335 During both apnea and IHG/ PECO reactivity protocols, there was no noted difference in
336 pressor responses to apnea or IHG/PECO in Lowlanders at low or high altitudes, with exception
337 to a lower TPR response under the PECO condition at altitude compared to sea level. Thus, the
338 current study demonstrates that overall cardiovascular reactivity was preserved during altitude
339 acclimatization 5050m. From the findings of both reactive conditions the vasoconstrictive
340 response was greater in Sherpa during apnea, but not IHG/PECO, which was shown in the

341 indirect transduction findings. We postulate two explanations for this disparity: 1) the magnitude
342 of the response to apnea was much larger than during the IHG/PECO protocol, and thus may
343 have been more robust for identifying differences in pressor responses between groups; and 2)
344 the lack of change in mean arterial pressure is representative of total systemic changes in TPR
345 and cardiac output. Thus, the modest increase in MSNA may not have had a significant
346 influence on altering mean arterial pressure. The subset of data evaluating brachial artery blood
347 flow support this hypothesis. Although our data do not support differences in the cardiovascular
348 response to small muscle mass recruitment in Sherpa, we acknowledge previous data which
349 suggests other cardiovascular adaptations in this population. Sherpa have previously been shown
350 to exhibit greater capillary density within skeletal muscle (19) and improved ability to increase
351 leg blood flow following 2 minutes of circulatory occlusion (32). Ezurum *et al.* (7)
352 subsequently demonstrated that Tibetans have higher resting forearm blood flow and circulating
353 NO by-products. These previous data support an improved dilatory capacity, but our data also
354 support a lower resting sympathetic activity, a greater sympathetic reserve and greater vascular
355 sensitivity to higher levels of sympathetic activity. Together, this may serve as an important
356 control mechanism for redirected blood and oxygen during stress. Thus, Sherpa appear to have
357 developed improved cardiovascular efficiency that does not rely to the same extent on
358 sympathetic hyperactivity relative to acclimatized Lowlanders. Whether this is expressed
359 through other high altitude populations remains to be determined.

360

361 **Considerations**

362 An interesting finding for Lowlanders was the lower total absolute MSNA responses to
363 apnea at high altitudes, despite basal MSNA being augmented at 5050m. As the apnea duration

364 was shorter, in combination with a lower post-breakpoint SpO₂ (indicative of an increase
365 chemoreceptor activation) (8, 39) , it can be argued that apnea at altitude is a greater sympathetic
366 stressor than it is at low altitude. However, the concurrent bradycardia which we have previously
367 reported on (3) likely limited sympathetic activation and could explain the appearance of
368 abnormal MSNA burst patterns at 5050m. This demonstrates a potential sympathetic “ceiling
369 effect” may have developed in Lowlanders, where further stress does not produce additional
370 MSNA activation. In other words, there is less MSNA reserve available for responding to acute
371 stress at altitude. MSNA outflow is limited to an individuals’ respective cardiac cycle, where a
372 finite degree of sympathetic augmentation can occur during each R-R interval (4, 24) . Whether
373 Sherpa truly have additional MSNA reserve available during apnea, or simply reached their own
374 respective sympathetic ceiling, cannot be confirmed due to us being unable to obtain sympathetic
375 reactivity in Sherpa at Kathmandu. However, the absence of abnormal burst pattern and a lower
376 average incidence of bursts in the cardiac cycles preceding break-point supports this premise.

377

378

379 Though we report that MSNA is lower across both basal and reactivity conditions for
380 Sherpa, the specific mechanism that contributes to this overall lower MSNA response has not yet
381 been determined. During the transition between acute to chronic hypoxia exposure there is an
382 apparent time-dependant sensitization for the peripheral chemoreceptors that results in
383 progressively heightened MSNA (5) . This is supported by a higher basal MSNA previously
384 observed by Hansen and Sander (13) and further confirmed by Lundby *et al.* (22) . If this were
385 true then it could be argued that attenuated chemoreflex sensitivity in Sherpa should explain their
386 lower basal MSNA. However, indirect measures of chemoreceptor sensitization do not appear to

387 explain the differences in MSNA between groups, as the current consensus (including more
388 recent publishing from this expedition) demonstrate similar hypoxic ventilatory responses
389 between acclimatized Lowlanders and Sherpa (1, 3, 10) . Though we do not believe the
390 peripheral chemoreflex is the primary driving mechanism for why sympathetic reactivity differs
391 between groups; we cannot completely exclude it given that ventilatory and sympathetic
392 responses may differ when under chemoreflex engagement (20) . Regardless, the lower MSNA
393 noted for Sherpa is likely attributed to a combination of other reflexes. These may include
394 differences in long-term potentiation of central regulatory mechanisms, central resetting, or
395 baroreflex-mediated changes between Lowlanders and Sherpa (12, 28, 42) ; the latter is
396 addressed in a parallel paper by this research group (35) .

397

398 **Limitations**

399 As testing of Lowlanders and Sherpa occurred during the initial 10 days of being at
400 5050m, we acknowledge that the findings within this study may be in part influenced by the
401 respective date individuals were tested at 5050m. As previously stated we assessed the potential
402 covariate of duration through Pearson's correlation and follow up ANCOVA analysis, where
403 neither burst frequency or incidence reached significance($P=0.065$ and $p=0.937$). However,
404 when examining baseline sympathetic function, and both sympathetic and vascular reactivity
405 between groups, there was no relationship following correction for the day they were tested at
406 5050m. We acknowledge the lack of relationship between duration of residency and resting
407 MSNA may be due to our small sample size. Although there may exist a gradual increase in
408 sympathetic activity following prolonged durations at altitude, this does not appear to have
409 affected our results of the current study. Furthermore, Lundby *et al.* (22) also showed that

410 MSNA was similar in acclimatized Lowlanders between days 10 and 50 at 4100 m. MSNA
411 therefore does not appear to increase further following several days at altitude, though the exact
412 period is currently undefined. However, we also acknowledge that degree of sympathetic
413 activation may be dose dependant with regards to the specific severity of hypoxic exposure (31)
414 . Whether MSNA shows further augmentation over the span of days-weeks should be considered
415 for future studies.

416 The use of voluntary apnea is a simple model of assessing muscle autonomic reactivity as
417 it evokes both a quick and large sympathetic response. However, apnea tolerance can be
418 objectively difficult to assess as duration can be affected by several factors including previous
419 repetitive practice overall tolerance to apneic stress between individuals (27) . This raises the
420 question of whether Sherpa truly demonstrated a maximal apnea at altitude. However, all
421 experimental procedures and manoeuvres were explained to Sherpa in Nepali and trials were
422 repeated if there was any confusion. In addition, Sherpa had both a similar apnea duration and
423 drop in SpO₂ to that of Lowlanders.

424 **Perspectives and Significance**

425 The current study demonstrates several novel findings, including that: 1) overall resting
426 MSNA activity and reactivity to apneic stress is lower in Sherpa at altitude; 2) sympathetic
427 reactivity to stress in acclimatized Lowlander appears to have be finite given the findings of a
428 potential “sympathetic ceiling”; and 3.) overall vascular reactivity was preserved during altitude
429 acclimatization 5050m in both Lowlanders and Sherpa, demonstrating that vascular
430 responsiveness to sympathetic activation may differ between groups. However, the specific
431 mechanisms that governs these differences between acclimatized Lowlanders and Sherpa is

432 uncertain. We propose that the observation of an apparent sympathetic plateauing observed in
433 Lowlanders indirectly supports a potentially greater sympathetic reserve at altitude for Sherpa,
434 though our findings from Kathmandu are underpowered to confirm this. Altered vascular
435 responsiveness in Sherpa may be a beneficial adaptation to generational residency that prevents
436 chronic hypertensive states while allowing greater vascular control when necessary to increased
437 physical demands at altitude. In general, further research is needed in order to delineate
438 underlying mechanisms that underpin autonomic and neurovascular control at high altitude in
439 native Sherpa.

440

441 **ACKNOWLEDGMENTS**

442 This study was carried out within the framework of the Ev-K2-CNR Project in collaboration with
443 the Nepal Academy of Science and Technology as foreseen by the Memorandum of
444 Understanding between Nepal and Italy (through contributions from the Italian National
445 Research Council). The authors dedicate this article to Dr. Chris Willie who tragically passed
446 away in 2017.

447

448 **SOURCES OF FUNDING**

449 This study was supported by the Natural Sciences and Engineering Research Council of Canada
450 (NSERC; CDS and PNA), a Presidents Grant for the Creative and Performance Arts – Human
451 Performance Scholarship (CDS), and a Canadian Research Chair in Cerebrovascular Physiology
452 (PNA).

453 **DISCOLSURES**

454 None

455 **FIGURE CAPTIONS**

456
457

458 **FIGURE 1:** Integrated neurogram demonstrating sympathetic activity during baseline (left) and
459 reactivity during apnea (right). Apnea shows last 10 cardiac cycles obtained prior to volitional
460 breakpoint. *Panel A,B,C.* Example of Neurogram from the same male at 355m (A) and 5050m
461 (B) against Sherpa at 5050m (C). Apnea at altitude caused prolonged burst periods and loss of
462 characteristic burst “peak” in Lowlanders . However, these prolonged burst remained contained
463 with a cardiac cycle. Sherpa did not develop prolonged burst firing patterns at 5050m.

464

465 **FIGURE 2:** Integral burst area (delta % change relative to baseline, mean± SD; denoted as
466 “#A”) and incidence of bursts (% of individuals who exhibited a burst during the respective
467 cardiac cycle, denoted as “#B”) within Lowlanders (n.=14) and Sherpa (n=8) during apnea.
468 Values represent 10 cardiac cycles prior to volitional breakpoint (indicated by dashed red line
469 along with mean apnea duration). *Panel 1,2,* Lowlanders at 344m (blue) and 5050m (orange),
470 *Panel 3,* Sherpa at 5050m (red). Maximum integrated burst area was determined as the highest
471 response during the 10 cardiac cycles for each participant. Burst incidence was calculated as the
472 number of individuals (represented as a %) exhibiting a burst during that respective cardiac
473 cycle. Lowlanders showed an increase in sympathetic activity prior to apnea breakpoint at both
474 low and high altitude (P<0.05). Multiple comparisons were assessed for integral burst area using
475 pre-planned contrasts of Lowlanders from low to high altitude (paired t-tests), and Lowlanders
476 to Sherpa at high altitude (unpaired t-tests) with an adjusted alpha value corrected for multiple
477 comparisons. Sherpa exhibited a smaller increase in burst area (P<0.05) versus Lowlanders at
478 5050m. The incidence of bursts in Lowlanders prior to volitional breakpoint was 100% while

479 incidence of bursts in Sherpa was 88%. * Significant difference from respective baseline $P < 0.05$;

480 † Significantly different from Lowlanders at high altitude, $P < 0.05$.

481
482 **FIGURE 3:** Bar graph (Mean \pm SD) representing the absolute changes from baseline in
483 normalized total peak SNA (au/min) and change in peak mean arterial pressure (mmHg) during
484 apnea. The normalized SNA represents the sum of SNA across the duration of 10 cardiac cycles.
485 The change in peak mean arterial pressure represents the change in peak blood pressure
486 immediately following (between 0-15 seconds) apnea breakpoint. Statistical analysis for
487 normalized total peak SNA and change in mean arterial pressure was performed via one-way
488 ANOVA between Lowlanders at low altitude, Lowlanders at High Altitude. All groups
489 exhibited a significant increase in MSNA and blood pressure. However, acclimatized
490 Lowlanders (5050m) and Sherpa (5050m) exhibited a smaller change in total SNA compared to
491 Lowlanders at low altitude (334m). Acclimatized Lowlanders (5050m) and Sherpa (5050m) also
492 had smaller blood pressure response compared to Lowlanders at low altitude (334m). *
493 Significant increase with respect to baseline, $P < 0.05$; † Significantly different from other groups,
494 $P < 0.05$, ‡ Significantly different from Lowlanders at 334m only, $P < 0.05$.

495
496 **FIGURE 4:** Line graph representing absolute burst frequency (Denoted as “A”; bursts/min),
497 incidence, (Denoted as “B”; bursts / 100 cardiac cycles) and total sympathetic activity (Denoted
498 as “C”; au) in Lowlanders at low altitude (n=14; white circle), high altitude (n=14; black circle),
499 and Sherpa at high altitude (n=6; black triangle) during the isometric handgrip and occlusion
500 protocol. Burst frequency, incidence, and total SNA during baseline, IHG, and PECO protocols,
501 a two-way repeated measures ANOVA compared the main and interaction effects in the
502 distributions between conditions. Lowlanders at exhibited both an interactive and main effect in

503 burst Frequency ($P<0.001$), and incidence ($P<0.001$). Sherpa exhibited an overall lower burst
504 frequency, incidence and total MSNA during the BL, IHG and PECO compared to acclimatized
505 Lowlanders (each $P<0.001$). During IHG burst frequency (all $P<0.001$), burst incidence (all
506 $P<0.001$) and total MSNA (all $P<0.001$) were elevated significantly in Lowlanders at 344m and
507 5050m, and Sherpa at 5050m respectively. No further increase in burst frequency or total MSNA
508 occurred between IHG and PECO, although burst incidence climbed due to the concurrent return
509 of heart rate to baseline during PECO (Figure 7). The increase in MSNA occurring with
510 IHG/PECO was not different between groups.

511
512 **FIGURE 5.** Line graph representing absolute Heart Rate (Denoted as “A”; bpm), Mean
513 Arterial Pressure, (Denoted as “B”; mmHg) and Total Peripheral Resistance (Denoted as “C”;
514 mmHg/L/min) in Lowlanders at low altitude (n=14; white circle), high altitude (n=14; black
515 circle), and Sherpa at high altitude (n=6; black triangle) during the isometric handgrip and
516 occlusion protocol. Heart rate, mean arterial pressure, and total peripheral resistance during
517 baseline, IHG, and PECO protocols, a two-way repeated measures ANOVA compared the main
518 and interaction effects in the distributions between conditions. While Sherpa tended to have an
519 overall lower blood pressure ($P<0.05$), the absolute change in blood pressure response to IHG
520 and PECO were similar between Sherpa ($+15\pm 4$ and $+12\pm 6$ mmHg) and Lowlanders ($+15\pm 6$
521 and $+12\pm 8$ mmHg) at 5050m (Figure 5). The change in total peripheral resistance was also
522 similar between Sherpa ($+2.6\pm 2.8$ and $+2.9\pm 2.9$ mmHg/L/min) and Lowlanders (-0.7 ± 1.9 and
523 $+0.6\pm 1.7$ mmHg/L/min) at 5050m . Thus, unlike the apnea protocol we did not detect
524 significant differences in neurovascular reactivity during IHG / PECO stress with altitude (in
525 Lowlanders) or between groups (at 5050m).

526

527

528 **Figure 6.** Line graph representing absolute Brachial Artery Flow (Denoted as “A”; mL/min),
529 Brachial Artery Resistance , (Denoted as “B”; mmHg/mL/min) and Brachial Artery Conductance
530 (Denoted as “C”;mmHg/L/min) in Lowlanders at low altitude (n=8; white circle), high altitude
531 (n=8; black circle), and Sherpa at high altitude (n=4; black triangle) during the isometric
532 handgrip and occlusion protocol. All vascular responses during baseline, IHG, and PECO
533 protocols, a two-way repeated measures ANOVA compared the main and interaction effects in
534 the distributions between conditions. Basal forearm blood flow was not different between
535 Lowlanders at 344m (46 ± 39 mL/min), 5050m (22 ± 42 mL/min), or Sherpa at 5050m (56 ± 24
536 mL/min). Both IHG and PECO saw no change in contralateral brachial blood flow for Sherpa
537 ($+29 \pm 25$ and $+12 \pm 8$ L/min) and Lowlanders ($+8 \pm 23$ and $+2 \pm 23$ L/min) at 5050m. The HG
538 and PECO protocols did not result in a change in contralateral brachial resistance for Sherpa (-
539 0.3 ± 1.1 and -0.9 ± 1.9 mmHg/mL/min) and Lowlanders (-0.6 ± 1.0 and -0.2 ± 0.9
540 mmHg/mL/min) at 5050m. There was a significant main effect for brachial artery conductance
541 ($P < 0.05$), with Lowlanders having a higher brachial artery conductance at altitude than Sherpa ,
542 though the absolute change during IHG and PECO were similar between Sherpa (-0.1 ± 0.3 and -
543 0.1 ± 0.4 mmHg/mL/min) and Lowlanders ($+0.3 \pm 0.3$ and $+0.5 \pm 0.5$ mmHg/mL/min) at 5050m.
544

545 **REFERENCES**

- 546 1. **Beall CM, Strohl KP, Blangero J, Williams-Blangero S, Almasy LA, Decker MJ,**
547 **Worthman CM, Goldstein MC, Vargas E, Villena M, Soria R, Alarcon AM and Gonzales**
548 **C.** Ventilation and hypoxic ventilatory response of Tibetan and Aymara high altitude
549 natives. *Am.J.Phys.Anthropol.* 104: 4: 427-447, 1997.
- 550 2. **Boyer SJ and Blume FD.** Weight loss and changes in body composition at high altitude.
551 *J.Appl.Physiol.Respir.Environ.Exerc.Physiol.* 57: 5: 1580-1585, 1984.
- 552 3. **Busch SA, Davies HE, Van Diepen S, Simpson LL, Sobierajski F, Riske L, Stembridge**
553 **M, Ainslie PN, Willie CK, Hoiland RL, Moore JP and Steinback CD.** Chemoreflex
554 Mediated Arrhythmia during Apnea at 5050m in Low but not High Altitude Natives.
555 *J.Appl.Physiol.(1985)* 2017.
- 556 4. **Delius W, Hagbarth KE, Hongell A and Wallin BG.** General characteristics of
557 sympathetic activity in human muscle nerves. *Acta Physiol.Scand.* 84: 1: 65-81, 1972.
- 558 5. **Dempsey JA, Powell FL, Bisgard GE, Blain GM, Poulin MJ and Smith CA.** Role of
559 chemoreception in cardiorespiratory acclimatization to, and deacclimatization from,
560 hypoxia. *J.Appl.Physiol.(1985)* 116: 7: 858-866, 2014.
- 561 6. **Duplain H, Vollenweider L, Delabays A, Nicod P, Bartsch P and Scherrer U.**
562 Augmented sympathetic activation during short-term hypoxia and high-altitude exposure
563 in subjects susceptible to high-altitude pulmonary edema. *Circulation* 99: 13: 1713-1718,
564 1999.

- 565 7. **Erzurum SC, Ghosh S, Janocha AJ, Xu W, Bauer S, Bryan NS, Tejero J, Hemann C, Hille**
566 **R, Stuehr DJ, Feelisch M and Beall CM.** Higher Blood Flow and Circulating NO Products
567 Offset High-Altitude Hypoxia among Tibetans. *Proc.Natl.Acad.Sci.U.S.A.* 104: 45: 17593-
568 17598, 2007.
- 569 8. **Eyzaguirre C and Lewin J.** Chemoreceptor activity of the carotid body of the cat.
570 *J.Physiol.(Lond.)* 159: 2: 222-237, 1961.
- 571 9. **Gilbert-Kawai E, Coppel J, Court J, van der Kaaij J, Vercueil A, Feelisch M, Levett D,**
572 **Mythen M, Grocott MP, Martin D and Xtreme Everest 2 Research Group.** Sublingual
573 microcirculatory blood flow and vessel density in Sherpas at high altitude.
574 *J.Appl.Physiol.(1985)* 122: 4: 1011-1018, 2017.
- 575 10. **Hackett PH, Reeves JT, Reeves CD, Grover RF and Rennie D.** Control of breathing in
576 Sherpas at low and high altitude. *J.Appl.Physiol.Respir.Environ.Exerc.Physiol.* 49: 3: 374-379,
577 1980.
- 578 11. **Hagbarth KE and Vallbo AB.** Pulse and respiratory grouping of sympathetic impulses
579 in human muscle-nerves. *Acta Physiol.Scand.* 74: 1: 96-108, 1968.
- 580 12. **Halliwill JR, Morgan BJ and Charkoudian N.** Peripheral Chemoreflex and Baroreflex
581 Interactions in Cardiovascular Regulation in Humans. *J.Physiol.* 552: Pt 1: 295-302, 2003.
- 582 13. **Hansen J and Sander M.** Sympathetic neural overactivity in healthy humans after
583 prolonged exposure to hypobaric hypoxia. *J.Physiol.* 546: Pt 3: 921-929, 2003.

- 584 14. **Herr MD, Hogeman CS, Koch DW, Krishnan A, Momen A and Leuenberger UA.** A
585 real-time device for converting Doppler ultrasound audio signals into fluid flow velocity.
586 298: 5: H1626-H1632, 2010.
- 587 15. **Hinkle DE, Wiersma W and Jurs SG.** Multiple-Comparison Procedures. In: *Applied*
588 *Statistic for the Behavioral Sciences* Anonymous . New York: Houghton Mifflin Company,
589 2003, p. 370-390.
- 590 16. **Hoppeler H, Howald H and Cerretelli P.** Human muscle structure after exposure to
591 extreme altitude. *Experientia* 46: 11-12: 1185, 1990.
- 592 17. **Hoppeler H and Vogt M.** Muscle tissue adaptations to hypoxia. *J.Exp.Biol.* 204: 18:
593 3133-3139, 2001.
- 594 18. **Katayama K, Ishida K, Iwamoto E, Iemitsu M, Koike T and Saito M.** Hypoxia
595 augments muscle sympathetic neural response to leg cycling.
596 *Am.J.Physiol.Regul.Integr.Comp.Physiol.* 301: 2: R456-64, 2011.
- 597 19. **Kayser B, Hoppeler H, Claassen H and Cerretelli P.** Muscle structure and
598 performance capacity of Himalayan Sherpas. *J.Appl.Physiol.(1985)* 70: 5: 1938-1942, 1991.
- 599 20. **Keir DA, Duffin J, Millar PJ and Floras JS.** Simultaneous assessment of central and
600 peripheral chemoreflex regulation of muscle sympathetic nerve activity and ventilation in
601 healthy young men. *J Physiol* 597: 13: 3281-3296, 2019.

- 602 21. **Leuenberger U, Gleeson K, Wroblewski K, Prophet S, Zelis R, Zwillich C and**
603 **Sinoway L.** Norepinephrine clearance is increased during acute hypoxemia in humans.
604 *Am.J.Physiol.* 261: 5 Pt 2: H1659-64, 1991.
- 605 22. **Lundby C, Calbet J, van Hall G, Saltin B and Sander M.** Sustained sympathetic activity
606 in altitude acclimatizing lowlanders and high-altitude natives. *Scand.J.Med.Sci.Sports* 2017.
- 607 23. **Macefield VG and Wallin BG.** Modulation of muscle sympathetic activity during
608 spontaneous and artificial ventilation and apnoea in humans. *J.Auton.Nerv.Syst.* 53: 2-3:
609 137-147, 1995.
- 610 24. **Macefield VG, Elam M and Wallin BG.** Firing properties of single postganglionic
611 sympathetic neurones recorded in awake human subjects. 95: 1-2: 146-159, 2002.
- 612 25. **Mitchell KM, Bradbury KE, Posch AM, Beidleman BA, Fulco CS, Muza SR and**
613 **Charkoudian N.** Influence of recent altitude exposure on sea level sympathetic neural &
614 hemodynamic responses to orthostasis. *Auton.Neurosci.* 210: 18-23, 2018.
- 615 26. **Murray AJ.** Energy metabolism and the high-altitude environment. *Exp.Physiol.* 101: 1:
616 23-27, 2016.
- 617 27. **Parkes MJ.** Breath-holding and its breakpoint. *Exp.Physiol.* 91: 1: 1-15, 2006.
- 618 28. **Querido JS, Wehrwein EA, Hart EC, Charkoudian N, Henderson WR and Sheel AW.**
619 Baroreflex control of muscle sympathetic nerve activity as a mechanism for persistent
620 sympathoexcitation following acute hypoxia in humans.
621 *Am.J.Physiol.Regul.Integr.Comp.Physiol.* 301: 6: R1779-85, 2011.

- 622 29. **Roberts AC, Butterfield GE, Cymerman A, Reeves JT, Wolfel EE and Brooks GA.**
623 Acclimatization to 4,300-m altitude decreases reliance on fat as a substrate.
624 *J.Appl.Physiol.*(1985) 81: 4: 1762-1771, 1996.
- 625 30. **Rowell LB, Johnson DG, Chase PB, Comess KA and Seals DR.** Hypoxemia raises
626 muscle sympathetic activity but not norepinephrine in resting humans.
627 *J.Appl.Physiol.*(1985) 66: 4: 1736-1743, 1989.
- 628 31. **Saito M, Mano T, Iwase S, Koga K, Abe H and Yamazaki Y.** Responses in muscle
629 sympathetic activity to acute hypoxia in humans. *J.Appl.Physiol.*(1985) 65: 4: 1548-1552,
630 1988.
- 631 32. **Schneider A, Greene RE, Keyl C, Bandinelli G, Passino C, Spadacini G, Bonfichi M,**
632 **Arcaini L, Malcovati L, Boiardi A, Feil P and Bernardi L.** Peripheral arterial vascular
633 function at altitude: sea-level natives versus Himalayan high-altitude natives. *J.Hypertens.*
634 19: 2: 213-222, 2001.
- 635 33. **Seals DR, Johnson DG and Fregosi RF.** Hypoxia potentiates exercise-induced
636 sympathetic neural activation in humans. *J.Appl.Physiol.* 71: 3: 1032-1040, 1991.
- 637 34. **Seals DR, Johnson DG and Fregosi RF.** Hypoxia potentiates exercise-induced
638 sympathetic neural activation in humans. *J.Appl.Physiol.*(1985) 71: 3: 1032-1040, 1991.
- 639 35. **Simpson LL, Busch SA, Oliver SJ, Ainslie PN, Stembridge M, Steinback CD and**
640 **Moore JP.** Baroreflex control of sympathetic vasomotor activity and resting arterial
641 pressure at high altitude: insight from Lowlanders and Sherpa. *J.Physiol.* 2019.

- 642 36. **Steinback CD and Kevin Shoemaker J.** Differential regulation of sympathetic burst
643 frequency and amplitude following acute hypoxia in humans.
644 *Am.J.Physiol.Regul.Integr.Comp.Physiol.* 303: 6: R633-8, 2012.
- 645 37. **Steinback CD and Kevin Shoemaker J.** Differential regulation of sympathetic burst
646 frequency and amplitude following acute hypoxia in humans.
647 *Am.J.Physiol.Regul.Integr.Comp.Physiol.* 303: 6: R633-8, 2012.
- 648 38. **Tymko MM, Tremblay JC, Steinback CD, Moore JP, Hansen AB, Patrician A, Howe**
649 **CA, Hoiland RL, Green DJ and Ainslie PN.** UBC-Nepal Expedition: Acute alterations in
650 sympathetic nervous activity do not influence brachial artery endothelial function at sea-
651 level and high-altitude. *J.Appl.Physiol.* 2017.
- 652 39. **Vidruk EH, Olson EB,Jr, Ling L and Mitchell GS.** Responses of single-unit carotid body
653 chemoreceptors in adult rats. *J.Physiol.* 531: Pt 1: 165-170, 2001.
- 654 40. **Willie CK, Stembridge M, Hoiland RL, Tymko MM, Tremblay JC, Patrician A,**
655 **Steinback C, Moore J, Anholm J, Subedi P, Niroula S, McNeil CJ, McManus A, MacLeod**
656 **DB and Ainslie PN.** UBC-Nepal Expedition: An experimental overview of the 2016
657 University of British Columbia Scientific Expedition to Nepal Himalaya. *PLoS One* 13: 10:
658 e0204660, 2018.
- 659 41. **Wu TY, Liu FY, Hu L, Wei CY, Wang ZG, Ouzhou-Loubu, Cu CY, Bianba, Qi XB and Su**
660 **B.** Hematological parameters in high altitude residents: Tibetan natives versus Han
661 migrants. *Zhongguo Ying Yong Sheng Li Xue Za Zhi* 30: 6: 516-525, 2014.

662 42. **Xie A, Skatrud JB, Puleo DS and Morgan BJ.** Exposure to hypoxia produces long-
663 lasting sympathetic activation in humans. *J.Appl.Physiol.(1985)* 91: 4: 1555-1562, 2001.

664

TABLE 1: Participant demographics and metrics of basal neuro-cardiovascular function in lowlanders (at 344m and 5050m) and Sherpa (at 5050m).

	LOWLANDERS		SHERPA
	344m (N = 14)	5050m (N = 14)	5050m (N = 8)
Subject Demographics			
Age (years)	27±6	27± 6	32±13
Height (m)	1.77±0.8	1.77± 0.08	1.68±0.08
Weight (kg)	72.2±10.1	69.4± 8.6	63.7±10.1
BMI (kg/m ²)	23.1±2.8	22.2±2.5	22.8±3.5
Resting Cardiovascular Function			
Heart Rate (bpm)	61 ± 15	70 ± 15*	71± 5
SPO ₂ (%)	98 ± 1	83 ± 3*	83 ± 4
Systolic Pressure (mmHg)	119 ± 9	113 ± 13	111 ± 9
Diastolic Pressure (mmHg)	66 ± 7	70 ± 10	65 ± 8
Mean Pressure (mmHg)	84 ± 8	86 ± 11	84 ± 9
Cardiac Output (L/min) ♦	5.9 ± 1.8	5.5 ± 1.4	6.0 ± 1.7
Total Peripheral Resistance ♦	15 ± 4	17 ± 4	16 ± 7
Resting Sympathetic Function			
Burst Frequency (burst min ⁻¹)	11 ± 5	30 ± 7*	23 ± 11*†
Burst Incidence (burst 100 HB ⁻¹)	25 ± 13	53 ± 15*	30 ± 13*†
Burst Amplitude (% of peak) •	42.1± 22.2	46.7±7.9	46.3± 19.1
Total Activity (au/min)	451 ± 206	1320 ± 520*	1103 ± 520*

♦ Derived from Model Flow calculation.

•Burst amplitude calculated as median and interquartile range

* Significantly different from Lowlanders tested at low altitude (344m); p < 0.05.

† Significantly different from Lowlanders tested at high altitude (5050m); p<0.05.

FIGURE 1




FIGURE 2




FIGURE 2




FIGURE 3






FIGURE 4

A



B



C






FIGURE 5

A



B



C




FIGURE 6

